Zimmer Biomet Holdings Inc. (NYSE:ZBH) reached a new 52-week high during trading on Thursday . The stock traded as high as $127.16 and last traded at $125.57, with a volume of 473,402 shares traded. The stock had previously closed at $126.49.

A number of equities research analysts have issued reports on ZBH shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $143.00 price objective (up from $134.00) on shares of Zimmer Biomet Holdings in a research report on Monday, July 18th. Argus raised shares of Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $140.00 price objective for the company in a research report on Wednesday, May 25th. Zacks Investment Research raised shares of Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $135.00 price objective for the company in a research report on Monday, July 4th. Guggenheim started coverage on shares of Zimmer Biomet Holdings in a research report on Wednesday, June 8th. They issued a “neutral” rating for the company. Finally, Morgan Stanley reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Wednesday, June 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $124.95.

The company has a market cap of $24.80 billion and a PE ratio of 306.60. The firm’s 50 day moving average is $120.95 and its 200-day moving average is $110.07.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.00 EPS for the quarter, topping analysts’ consensus estimates of $1.93 by $0.07. The company earned $1.90 billion during the quarter, compared to the consensus estimate of $1.88 billion. The business’s revenue was up 67.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.54 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings Inc. will post $7.96 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, June 24th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, June 22nd. This represents a $0.96 annualized dividend and a yield of 0.77%.

In related news, insider Stuart G. Kleopfer sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, June 9th. The shares were sold at an average price of $119.45, for a total transaction of $1,313,950.00. Following the completion of the sale, the insider now directly owns 7,609 shares in the company, valued at $908,895.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Tony W. Collins sold 3,611 shares of the business’s stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $116.43, for a total transaction of $420,428.73. Following the sale, the chief accounting officer now owns 3,245 shares of the company’s stock, valued at $377,815.35. The disclosure for this sale can be found here.

A number of hedge funds have made changes to their positions in the stock. Vanguard Group Inc. acquired a new stake in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $1,006,696,000. Eaton Vance Management acquired a new stake in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $86,854,000. Jennison Associates LLC acquired a new stake in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $71,968,000. Levin Capital Strategies L.P. acquired a new stake in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $69,610,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Zimmer Biomet Holdings during the fourth quarter valued at about $66,348,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.